These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 31582580)

  • 41. Population pharmacokinetics of free flucloxacillin in patients treated with oral flucloxacillin plus probenecid.
    Drennan PG; Green JK; Gardiner SJ; Metcalf SCL; Kirkpatrick CMJ; Everts RJ; Zhang M; Chambers ST
    Br J Clin Pharmacol; 2021 Dec; 87(12):4681-4690. PubMed ID: 33963595
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Benzylpenicillin versus flucloxacillin for penicillin-susceptible Staphylococcus aureus bloodstream infections from a large retrospective cohort study.
    Henderson A; Harris P; Hartel G; Paterson D; Turnidge J; Davis JS; Tong SYC
    Int J Antimicrob Agents; 2019 Oct; 54(4):491-495. PubMed ID: 31181352
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Oral flucloxacillin in septicaemia.
    Gobbo O; Street A; Bury RW; Moulds RF
    Med J Aust; 1992 Oct; 157(8):575. PubMed ID: 1479999
    [No Abstract]   [Full Text] [Related]  

  • 44. Early termination of a prospective, randomized trial comparing teicoplanin and flucloxacillin for treating severe staphylococcal infections.
    Calain P; Krause KH; Vaudaux P; Auckenthaler R; Lew D; Waldvogel F; Hirschel B
    J Infect Dis; 1987 Feb; 155(2):187-91. PubMed ID: 2949024
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Probenecid and food effects on flucloxacillin pharmacokinetics and pharmacodynamics in healthy volunteers.
    Everts RJ; Begg R; Gardiner SJ; Zhang M; Turnidge J; Chambers ST; Begg EJ
    J Infect; 2020 Jan; 80(1):42-53. PubMed ID: 31521742
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.
    Adane ED; Herald M; Koura F
    Pharmacotherapy; 2015 Feb; 35(2):127-39. PubMed ID: 25644478
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ceftaroline fosamil for treatment of diabetic foot infections: the CAPTURE study experience.
    Lipsky BA; Cannon CM; Ramani A; Jandourek A; Calmaggi A; Friedland HD; Goldstein EJ
    Diabetes Metab Res Rev; 2015 May; 31(4):395-401. PubMed ID: 25417910
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Three-times-weekly, post-dialysis cefepime therapy in patients on maintenance hemodialysis: a retrospective study.
    Descombes E; Martins F; Hemett OM; Erard V; Chuard C
    BMC Pharmacol Toxicol; 2016 Feb; 17():4. PubMed ID: 26846675
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Pharmacokinetics of free and total flucloxacillin in newborn infants.
    Herngren L; Ehrnebo M; Broberger U
    Eur J Clin Pharmacol; 1987; 32(4):403-9. PubMed ID: 3609118
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Interaction of flucloxacillin and quinidine.
    Comuth WJ; Comuth JA; Hauer RN; Malingré MM
    Eur J Clin Pharmacol; 2012 May; 68(5):891-3. PubMed ID: 22203424
    [No Abstract]   [Full Text] [Related]  

  • 51. Bactericidal activity of flucloxacillin against Staphylococcus aureus in primary keratinocyte cultures of lesional and unaffected skin of patients suffering from atopic dermatitis.
    Vollmert C; Behrendt H
    Exp Dermatol; 2005 Mar; 14(3):215-24. PubMed ID: 15740595
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Evaluation of an institutional guideline for the treatment of cerebrospinal fluid shunt-associated infections.
    von der Brelie C; Simon A; Gröner A; Molitor E; Simon M
    Acta Neurochir (Wien); 2012 Sep; 154(9):1691-7. PubMed ID: 22454037
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Staphylococcus aureus carriage rates and antibiotic resistance patterns in patients with acne vulgaris.
    Delost GR; Delost ME; Armile J; Lloyd J
    J Am Acad Dermatol; 2016 Apr; 74(4):673-8. PubMed ID: 26777099
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Flucloxacillin in the treatment of atopic dermatitis.
    Ewing CI; Ashcroft C; Gibbs AC; Jones GA; Connor PJ; David TJ
    Br J Dermatol; 1998 Jun; 138(6):1022-9. PubMed ID: 9747366
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Does routine prophylactic oral flucloxacillin reduce the incidence of post-circumcision infections?
    Lebina L; Laher F; Mukudu H; Essien T; Otwombe K; Gray G; Martinson N
    Am J Infect Control; 2013 Oct; 41(10):897-900. PubMed ID: 23489735
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Protein binding of flucloxacillin in neonates.
    Pullen J; Stolk LM; Degraeuwe PL; van Tiel FH; Neef C; Zimmermann LJ
    Ther Drug Monit; 2007 Jun; 29(3):279-83. PubMed ID: 17529883
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Flucloxacillin treatment of methicillin-'resistant' and sensitive staphylococcal infection.
    Kidson A; Lilly HA; Lowbury EJ
    J Antimicrob Chemother; 1979 Jul; 5(4):359-64. PubMed ID: 489489
    [No Abstract]   [Full Text] [Related]  

  • 58. Antibiotic route and duration of therapy for cellulitis: data extracted from a multi-center clinical trial.
    Williams OM; Brindle R
    Int J Antimicrob Agents; 2020 Sep; 56(3):106076. PubMed ID: 32629112
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Probability of pharmacological target attainment with flucloxacillin in Staphylococcus aureus bloodstream infection: a prospective cohort study of unbound plasma and individual MICs.
    Moser S; Rehm S; Guertler N; Hinic V; Dräger S; Bassetti S; Rentsch KM; Sendi P; Osthoff M
    J Antimicrob Chemother; 2021 Jun; 76(7):1845-1854. PubMed ID: 33860325
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Oral antibiotic therapy of serious systemic infections.
    Cunha BA
    Med Clin North Am; 2006 Nov; 90(6):1197-222. PubMed ID: 17116444
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.